Bolden Therapeutics
- Biotech or pharma, therapeutic R&D
Bolden Therapeutics is a preclinical stage biotech company developing novel therapies to repair the diseased brain and accelerate muscle recovery. Our founders discovered a novel signaling pathway that regulates the activity of adult stem cells in brain and in muscle. Bolden has validated its novel drug target genetically demonstrating increased neurogenesis and cognition, as well as increased muscle size, strength, and recovery following injury. We have also recently shown that our antisense oligonucleotide drug candidate is well tolerated, achieves selective target engagement, and promotes neurogenesis in adult mice, achieving in vivo efficacy. We are currently raising a $4M Seed round to support drug development up to IND-enabling studies for our lead ASO program for CNS indications and also early-stage development for a monoclonal antibody program for muscle indications. In parallel, we are seeking industry partnerships to accelerate our development to help improve patients' lives.
Address
ProvidenceRhode Island
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}